These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37437516)
21. Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group. Gaetani E; Agostini F; Porfidia A; Giarretta I; Feliciani D; Di Martino L; Tortora A; Gasbarrini A; Pola R; Orphanet J Rare Dis; 2019 Dec; 14(1):298. PubMed ID: 31878955 [TBL] [Abstract][Full Text] [Related]
22. Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians. Al-Samkari H Semin Thromb Hemost; 2022 Jul; 48(5):514-528. PubMed ID: 35226946 [TBL] [Abstract][Full Text] [Related]
23. Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals. Yokoi H; Oda E; Kaneko K; Matsubayashi K Cardiovasc Interv Ther; 2022 Jul; 37(3):465-474. PubMed ID: 35141843 [TBL] [Abstract][Full Text] [Related]
24. Risk of rebleeding, vascular events and death after gastrointestinal bleeding in anticoagulant and/or antiplatelet users. Sostres C; Marcén B; Laredo V; Alfaro E; Ruiz L; Camo P; Carrera-Lasfuentes P; Lanas Á Aliment Pharmacol Ther; 2019 Oct; 50(8):919-929. PubMed ID: 31486121 [TBL] [Abstract][Full Text] [Related]
25. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Epperla N; Hocking W Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223 [TBL] [Abstract][Full Text] [Related]
26. Hemorrhage rates from brain arteriovenous malformation in patients with hereditary hemorrhagic telangiectasia. Kim H; Nelson J; Krings T; terBrugge KG; McCulloch CE; Lawton MT; Young WL; Faughnan ME; Stroke; 2015 May; 46(5):1362-4. PubMed ID: 25858236 [TBL] [Abstract][Full Text] [Related]
27. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841 [TBL] [Abstract][Full Text] [Related]
28. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111 [TBL] [Abstract][Full Text] [Related]
29. Lower Risk of Intracranial Arteriovenous Malformation Hemorrhage in Patients With Hereditary Hemorrhagic Telangiectasia. Yang W; Liu A; Hung AL; Braileanu M; Wang JY; Caplan JM; Colby GP; Coon AL; Tamargo RJ; Ahn ES; Huang J Neurosurgery; 2016 May; 78(5):684-93. PubMed ID: 26540357 [TBL] [Abstract][Full Text] [Related]
30. Effect of preoperative antiplatelet or anticoagulation therapy on hemorrhagic complications in patients with traumatic brain injury undergoing craniotomy or craniectomy. Greuter L; Ullmann M; Mariani L; Guzman R; Soleman J Neurosurg Focus; 2019 Nov; 47(5):E3. PubMed ID: 31675713 [TBL] [Abstract][Full Text] [Related]
31. Abdominal manifestations of hereditary hemorrhagic telangiectasia: a series of 333 patients over 15 years. Welle CL; Welch BT; Brinjikji W; Ehman EC; Venkatesh SK; Johnson MP; Iyer VN; Leise MD; Wood CP Abdom Radiol (NY); 2019 Jul; 44(7):2384-2391. PubMed ID: 30888464 [TBL] [Abstract][Full Text] [Related]
32. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329 [TBL] [Abstract][Full Text] [Related]
33. Clinical features and treatment of hereditary hemorrhagic telangiectasia. Li S; Wang SJ; Zhao YQ Medicine (Baltimore); 2018 Aug; 97(31):e11687. PubMed ID: 30075565 [TBL] [Abstract][Full Text] [Related]
35. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation? Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873 [TBL] [Abstract][Full Text] [Related]
36. [Clinical features of intracerebral hemorrhage under antithrombotic therapy in the warfarin era]. Kohama M; Yoshida M; Mino M; Tominaga T No Shinkei Geka; 2015 Mar; 43(3):199-205. PubMed ID: 25748804 [TBL] [Abstract][Full Text] [Related]
37. Hospitalizations with hereditary hemorrhagic telangiectasia and pulmonary hypertension in the United States from 2000 to 2014. Harder EM; Fares WH Respir Med; 2019 Feb; 147():26-30. PubMed ID: 30704695 [TBL] [Abstract][Full Text] [Related]
38. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia]. Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875 [TBL] [Abstract][Full Text] [Related]
39. Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study. Kroon S; Snijder RJ; Hosman AE; Vorselaars VMM; Disch FJM; Post MC; Mager JJ Angiogenesis; 2021 May; 24(2):379-386. PubMed ID: 33211216 [TBL] [Abstract][Full Text] [Related]
40. Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses. González-Pérez A; Sáez ME; Johansson S; Himmelmann A; García Rodríguez LA BMC Cardiovasc Disord; 2016 Aug; 16(1):164. PubMed ID: 27577589 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]